Picture of Bioxytran logo

BIXT Bioxytran Income Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapNeutral

Annual income statement for Bioxytran, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

2017
December 31st
C2018
December 31st
2019
December 31st
2020
December 31st
2021
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:10-K10-K10-K10-K10-K
Standards:
USG
USG
USG
USG
USG
Status:FinalFinalFinalFinalFinal
Revenue
Total Revenue0.1910000
Cost of Revenue
Gross Profit0.087
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Total Operating Expenses0.5020.2151.631.274.21
Operating Profit-0.311-0.215-1.63-1.27-4.21
Total Net Non Operating Interest Income / Expense
Net Income Before Taxes-0.318-0.296-1.86-2.54-4.53
Provision for Income Taxes
Net Income After Taxes-0.318-0.296-1.86-2.54-4.53
Minority Interest
Net Income Before Extraordinary Items
Extraordinary Items
Net Income-0.318-0.296-1.86-2.48-4.03
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income-0.318-0.296-1.86-2.48-4.03
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS-0.242-0.003-0.022-0.026-0.038

Or unlock with your email

Or unlock with your email